Articles tagged with Glaucoma
Researchers from RUDN University designed new compounds that selectively inhibit human carbonic anhydrase, reducing intraocular pressure and potentially treating glaucoma. The study's findings suggest a promising approach for developing new antiglaucoma drugs by modifying the compound's molecular periphery.
Researchers at Georgia Institute of Technology have identified a rare Y-shape in a protein associated with hereditary glaucoma, which may revolutionize its treatment. The discovery reveals how the Y ties together major components of the protein and could help understand myocilin's role in the eye.
Researchers successfully used CRISPR-Cas9 to eliminate the mutated myocilin protein, which led to lowered intraocular pressure and prevented glaucomatous damage in mouse eyes. This breakthrough study could pave the way for a new therapy to treat myocilin glaucoma in humans.
Researchers at IBS have identified a new mechanism involved in glaucoma development and progression, and found a potential therapeutic option to treat primary open-angle glaucoma. The study highlights the critical role of the angiopoietin-Tie2 system in Schlemm's canal functionality.
The University of North Carolina at Chapel Hill is developing an intervention to empower patients with glaucoma to take a more active role in their treatment. The study aims to improve communication between patients and ophthalmologists, leading to better medication adherence and reduced intraocular pressure.
A new biomarker, GDF15, has been identified as a potential predictor of vision loss in glaucoma patients. The biomarker, which measures stress to cells rather than cell death, was found to be elevated in mice and humans with glaucoma, correlating with disease severity.
Researchers at Medical College of Georgia are exploring the potential of (+)-pentazocine to prevent vision damage in glaucoma patients by activating sigma-1 receptors in astrocytes. The study aims to understand how increased pressure affects astrocyte behavior and develop new therapies to protect neurons.
A new eye test has been developed to detect the earliest signs of glaucoma, allowing for early treatment and potential reversal of vision loss. The test uses a specialized fluorescent marker to identify individual nerve cell death in the back of the eye.
A study published in JAMA Ophthalmology found that patients with age-related macular degeneration who received seven or more eye injections of bevacizumab annually had a higher risk of developing moderate to advanced glaucoma. This increased risk was associated with the potential for elevated intraocular pressure, highlighting the need...
Researchers found that vitamin B3 administration eliminated age-related molecular changes and provided robust protection against glaucoma. The treatment boosted metabolic reliability of aging retinal ganglion cells, keeping them healthier for longer.
Researchers at the University of Rochester Medical Center have developed a new imaging technique that can distinguish individual retinal ganglion cells, which bear most of the responsibility for relaying visual information to the brain. This breakthrough could enable earlier diagnosis and treatment of eye diseases like glaucoma.
A new study has found a possible link between the Zika virus and glaucoma in infants exposed to the virus during gestation. Researchers identified a three-month-old boy with symptoms of glaucoma caused by Zika exposure, leading to successful treatment via trabeculectomy.
Researchers use optimal coherence tomography (OCT) angiography to identify characteristic patterns of different forms of glaucoma based on their vascular patterns. This breakthrough technology could lead to earlier diagnosis and potentially slow down the progression of vision loss.
Scientists found a link between overexpression of the miR-182 gene and increased eye pressure in primary open-angle glaucoma patients. The study suggests that this variation may contribute to the disease's destructive effects on vision.
A study suggests that stem cell infusion could help restore the trabecular meshwork, which drains fluid from the eye and prevents glaucoma. Researchers are confident that this approach may hold promise for primary open angle glaucoma, but further studies are needed to confirm its effectiveness.
Scientists at Hokkaido University measured eye pressure in sleeping patients with obstructive sleep apnea syndrome for the first time, discovering an unexpected correlation between the two conditions. This study sheds light on the potential mechanisms underlying glaucoma development in patients with OSAS.
Researchers at the University of New South Wales have developed a new eye test that can detect glaucoma four years earlier than current techniques. The patented method involves patients looking at small dots of light of specially chosen size and light intensity, identifying blind spots in the eye and early loss of peripheral vision.
A University of Georgia study found that medical marijuana leads to lower prescription drug use, particularly for conditions like glaucoma and pain. The study estimated savings of $468 million if all states had implemented medical marijuana laws.
A new clinical trial shows that modulating brain plasticity can partially restore vision in patients with glaucoma and optic nerve damage after 10 days of noninvasive stimulation. The treatment improved visual acuity, reading, mobility, and orientation, with benefits stable two months later.
Researchers have identified a genetic mutation in the TEK gene that causes primary congenital glaucoma, a devastating eye disease affecting children worldwide. The finding validates previous research in mice and suggests a new therapeutic pathway to repair damaged vessels in the eye.
Researchers have developed a medicated silicone ring that slowly releases medication over 6 months, potentially lowering the risk of vision loss among seniors with glaucoma. The device reduced eye pressure by about 20% in patients compared to traditional daily drops.
The BrightFocus Foundation has awarded nearly $5 million in vision research grants to five scientists studying macular degeneration and glaucoma. The grants, named after prominent leaders in the field, will support innovative research projects aimed at understanding and preventing these diseases.
Accurate IOP measurement is crucial for managing glaucoma and identifying high-risk patients. Newer methods like Dynamic Contour Tonometry offer alternative solutions for patients with abnormal corneas, but limitations remain.
Researchers developed a compound called KUSs that may help prevent nerve damage in glaucoma, allowing patients to maintain near-normal vision. Early tests in mice showed promising results, suggesting these compounds could slow down disease progression and potentially treat other neurodegenerative diseases.
Scientists create method to differentiate patient-derived stem cells into retinal ganglion cells, which can help combat neurodegeneration in glaucoma. This breakthrough enables personalized medicine prospects for patients with glaucoma.
Researchers at IUPUI have successfully identified cellular processes related to glaucoma using stem cells derived from human skin cells. The study found that skin cells from individuals with glaucoma became unhealthy and died off faster than those of healthy individuals when reprogrammed into retinal ganglion cells.
A study published in JAMA Ophthalmology found that higher dietary nitrate and green leafy vegetable intake is associated with a lower risk of primary open-angle glaucoma. Participants who consumed more nitrate-rich foods had a 20-30% reduced risk of developing the condition.
The study, funded by the National Eye Institute, identified FOXC1, TXNRD2, and ATXN2 as contributing genes to primary open-angle glaucoma. Variations in these genes may lead to reduced mitochondrial protection, increasing optic nerve cell death.
Researchers have identified three genetic associations that influence susceptibility to primary open angle glaucoma, a leading cause of irreversible blindness. The study found associations between TXNRD2, ATXN2, and FOXC1 genes, which may lead to the development of gene-based screening tests and therapy for glaucoma patients.
Researchers found that head-down yoga poses, such as downward-facing dog, can cause a rise in eye pressure in glaucoma patients. Glaucoma patients should inform their yoga instructors about their condition to modify poses and avoid potential damage to the optic nerve.
A survey of glaucoma patients in Washington, D.C. found that perceptions of marijuana legality and false beliefs about its value were associated with intentions to use it as a treatment. The study suggests a need for education on the topic to protect patients against increased acceptability based on misconceptions.
A study found that patients with glaucoma can adapt their visual scanning behavior to compensate for impaired vision and pass a standard driving test. By making more frequent head and eye movements, they can improve traffic safety and potentially be granted a driver's license in some countries.
Washington State University researchers created a sensing platform to measure and analyze gait patterns in people with glaucoma. This innovation aims to reduce falls and injuries by detecting early signs of the disease, such as slower walking pace and unequal step placement.
Bamosiran reduced IOP by similar magnitude across four doses, but failed to demonstrate non-inferiority to timolol in total population; showed excellent tolerability and non-inferiority at dose 1.125% in patients with baseline IOP >=25mmHg
Scientists at UC San Diego School of Medicine have elucidated a genetic interaction between SIX6 and p16INK4a that may prove key to the development and progression of glaucoma. Inhibiting p16INK4a expression could offer a new therapeutic approach for the disease, which is currently treated by lowering intraocular pressure.
Researchers have discovered the molecular culprits behind primary open-angle glaucoma, a leading cause of blindness, by identifying two key risk genes: SIX6 and P16. The study found that high eye pressure increases expression of P16, linking it to increased risk of vision loss.
Krishnakumar Kizhatil has been awarded the prestigious Lewis Rudin Glaucoma Prize for his research on Schlemm's canal, a unique vessel that plays a key role in glaucoma. The prize recognizes Kizhatil's work as a major breakthrough in understanding the molecular basis of intraocular pressure elevation and its link to glaucoma.
Researchers found that the brain coordinates vision loss in glaucoma patients, with a 'Jigsaw Effect' where two puzzle pieces fit together. This suggests that the brain optimizes vision in the face of glaucoma's destruction of sight, opening up new areas of research for neuroprotective therapies.
A study published in JAMA Ophthalmology has found associations between lower blood manganese levels and higher blood mercury levels with a greater risk of glaucoma diagnosis. The research suggests that trace metals may play a role in the pathogenesis of glaucoma, and future investigations could explore potential neuroprotective effects.
BrightFocus Foundation has awarded $11 million in research grants to 58 scientists worldwide. The grants focus on treatments for age-related diseases such as Alzheimer's, glaucoma, and macular degeneration, with a emphasis on early detection, disease progression, and potential interventions.
A study published in JAMA Ophthalmology found that patients taking metformin hydrochloride had a 25% reduced risk of developing open-angle glaucoma compared to those who took no metformin. Higher doses of metformin were associated with greater reductions in OAG risk, suggesting potential benefits for eye health.
A study of 3,353 Chinese adults in Singapore found the prevalence of glaucoma to be 3.2%, with primary open-angle glaucoma affecting 1.7% and primary angle-closure glaucoma affecting 1.5%. The study also highlighted the need for increased public awareness of this potentially blinding condition.
A new virtual reality testing environment provides a more realistic assessment of balance control in glaucoma patients. The study found that patients with glaucoma made balance adjustments 30-40% more pronounced than healthy subjects, highlighting the need for preventative measures.
A researcher at IUPUI is studying how glaucoma develops in stem cells created from skin cells genetically predisposed to the disease. The goal is to identify the cause of damage and develop customized strategies to fix it, potentially leading to repairing existing cells and restoring vision.
Researchers identified structural features and cell types in the retina that may act as key factors in glaucoma progression. Within seven days of elevated eye pressure, some retinal ganglion cells underwent significant rearrangements, such as reductions in number and length of dendritic branches.
A new study finds that chronic hypertension increases a person's susceptibility to glaucoma by damaging blood vessels in the eye. This damage compromises the eye's capacity to cope with changes in blood flow, making hypertension a risk factor for the potentially blinding eye disorder.
A study published in The Lancet found that prostaglandin analogue eye drops can reduce the risk of vision loss in people with open angle glaucoma by over 50% over 2 years. The treatment showed significant benefits even after just 12 months, and more frequent testing can lead to faster data collection and improved drug development.
Glaucoma, affecting over 60 million worldwide, has been linked to mitochondrial gene mutations through DNA sequencing. The research aims to support personalized medicines targeting mutated mitochondria and prevent disease progression.
A new study from City University London found that eye movement analysis can detect diseases like glaucoma while watching TV. This method could help clinicians identify the disease earlier, enabling timely treatment before permanent damage occurs.
A study using a free peripheral vision assessment app on iPads screens approximately 200 patients in Nepal for glaucoma, showing promise for populations with limited access to traditional eye care. The results agree between 51-79% with the industry standard test and can be an effective initial screening tool for high-risk groups.
A study led by Queen's University professor Robert Campbell revealed that using anti-inflammatory medicines after common eye surgery isn't helpful or necessary. The research found that steroids and nonsteroidal anti-inflammatory drugs do not affect the ability of laser treatment to lower eye pressure.
Researchers found that endothelial cells in eyes with glaucoma are stiffer than healthy cells, leading to increased flow resistance and elevated pressure. This mechanical dysfunction may lead to a cure for the debilitating disease.
Researchers at Northwestern University identify a critical chemical signaling pathway for the healthy functioning of Schlemm's canal, a key factor in developing glaucoma. They are now developing an eye drop that activates regrowth of the clogged vessel to lower pressure and restore normal drainage.
The Stanford-developed eye implant is a tiny device that measures intraocular fluid flow and provides data on eye pressure. This information can help doctors tailor treatment plans, potentially improving outcomes for glaucoma patients. The device is currently designed to fit inside a standard intraocular lens prosthetic.
Schlemm's canal has been found to have lymphatic characteristics, including a growth factor that reduces eye pressure. This discovery challenges the current understanding of the eye's drainage system and opens up new avenues for glaucoma treatment and diagnosis.
A new study published in PLOS Biology reveals that Schlemm's canal forms from blood vessels through a novel process called canalogenesis. This discovery sheds light on the complex functions of Schlemm's canal, which plays a critical role in maintaining ocular health and preventing diseases like glaucoma.
Researchers have discovered that acute glaucoma is an inflammatory disease caused by high eye pressure, leading to vision loss. The study found that a rapid increase in eye pressure triggers an immune response that damages retinal cells.
Researchers at the University of Washington have designed a low-power sensor to track eye pressure changes and monitor for glaucoma. The sensor would be embedded with an artificial lens during cataract surgery and transmit data wirelessly, allowing for real-time tracking and potentially preventing vision loss.
A new study published in TVST found that glaucoma is controlled by the brain, not the eye. The research shows that as previously disabled optic nerve axons recover, the remaining areas of permanent visual loss coincide with the areas that can still see in the other eye, forming a jigsaw puzzle-like pattern.
Two studies in JAMA Ophthalmology investigated glaucoma medication adherence, finding that a sizable number of patients struggle to use prescribed eye drops. Electronic monitoring revealed that 82.8% of patients took their medication correctly on at least 75% of days, highlighting the need for risk calculators to identify nonadherent p...